Molecular MRI-Based Monitoring of Cancer Immunotherapy Treatment Response
Nikita Vladimirov (1), Or Perlman (1, 2) ((1) Department of, Biomedical Engineering, Tel Aviv University, Tel Aviv, Israel, (2) Sagol, School of Neuroscience, Tel Aviv University, Tel Aviv, Israel)

TL;DR
This review discusses recent advances in molecular MRI techniques for noninvasively monitoring cancer immunotherapy, emphasizing biological insights, AI integration, and potential for early response detection.
Contribution
It provides a comprehensive overview of molecular MRI methods, their physics, biological basis, and emerging AI strategies for improved immunotherapy monitoring.
Findings
Molecular MRI can detect early biological changes during immunotherapy.
AI enhances analysis and interpretation of MRI data.
Preclinical and clinical studies show promising results.
Abstract
Immunotherapy constitutes a paradigm shift in cancer treatment. Its FDA approval for several indications has yielded improved prognosis for cases where traditional therapy has shown limited efficiencey. However, many patients still fail to benefit from this treatment modality, and the exact mechanisms responsible for tumor response are unknown. Noninvasive treatment monitoring is crucial for longitudinal tumor characterization and the early detection of non-responders. While various medical imaging techniques can provide a morphological picture of the lesion and its surrounding tissue, a molecular-oriented imaging approach holds the key to unraveling biological effects that occur much earlier in the immunotherapy timeline. Magnetic resonance imaging (MRI) is a highly versatile imaging modality, where the image contrast can be tailored to emphasize a particular biophysical property of…
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
